Albireo Pharma, Inc. (ALBO)
| Market Cap | 712.22M |
| Revenue (ttm) | 12.02M |
| Net Income (ttm) | -90.36M |
| Shares Out | 15.70M |
| EPS (ttm) | -6.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $36.68 |
| Previous Close | $36.78 |
| Change ($) | -0.10 |
| Change (%) | -0.27% |
| Day's Open | 36.70 |
| Day's Range | 36.32 - 37.86 |
| Day's Volume | 102,261 |
| 52-Week Range | 11.26 - 49.00 |
Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of i...
– Company outlining large global rare cholestatic liver disease opportunity –
Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications. The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasi...
Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases Albireo supports the Alagille syndrome community ...
BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of i...
BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will h...
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of i...
BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced th...
- Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients -
- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus -
- P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 -
- Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases-
Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases Albireo stands together with the PFIC comm...
BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced th...
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today...
BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today...
Albireo Pharma (ALBO) is in the news Tuesday after positive results from a recent clinical trial sent ALBO stock soaring higher. The post Albireo Pharma News: Why ALBO Stock Is Soaring 45% Tod...
The company reported positive data from a clinical trial.
-Highly statistically significant reductions in both pruritus and serum bile acids-
— Conference call and webcast to be held at 8:30 a.m. EDT — — Conference call and webcast to be held at 8:30 a.m. EDT —
Investors need to pay close attention to Albireo Pharma (ALBO) stock based on the movements in the options market lately.
Albireo (ALBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.
‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒
Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q2 2020 Results - Earnings Call Transcript
— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials —— Enrolled first biliary atresia patients in second odevixibat pivotal study —— Completed two financing transactions ...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
— Conference call and webcast to be held at 10:00 a.m. ET —
— Program expands access to odevixibat for patients with progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease — — Program expands access to o...
— BOLD is first-ever pivotal trial for biliary atresia —
Investors need to pay close attention to Albireo (ALBO) stock based on the movements in the options market lately.
Albireo Pharma (ALBO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
BOSTON, June 10, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
— Restructured HealthCare Royalty Partners elobixibat royalty monetization agreement nets additional $15M in non-dilutive capital —
Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q1 2020 Results - Earnings Call Transcript
Shares of Albireo Pharma (NASDAQ:ALBO) were flat in pre-market trading after the company reported Q1 results.
BOSTON, April 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced...
Albireo Pharma like so many small biotech names has been hit hard during the recent COVID-19 market meltdown.
On track to report topline data mid-2020
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2019 Results - Earnings Call Transcript
Albireo Pharma: View Ahead Of Phase 3 Data In Progressive Familial Intrahepatic Cholestasis In Mid-2020
BOSTON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
BOSTON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
— Reiterates Top Line Data on Phase 3 in PFIC Expected Mid-2020 — — To Initiate Pivotal Trials in Biliary Atresia and Alagille Syndrome in 2020 —
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2019 Results - Earnings Call Transcript
Senior leader with demonstrated experience building high-performing businesses and teams Senior leader with demonstrated experience building high-performing businesses and teams
Presentations highlight data on odevixibat’s minimal systemic exposure and Albireo’s proprietary pruritus assessment tools Presentations highlight data on odevixibat’s minimal systemic exposur...
BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced...
About ALBO
Albireo Pharma, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treat... [Read more...]
| Industry Biotechnology | |
| CEO Gary Gemignani | Employees 55 |
| Stock Exchange NASDAQ | Ticker Symbol ALBO |
Financial Performance
In 2019, Albireo Pharma's revenue was $9.64 million, a decrease of -24.36% compared to the previous year's $12.74 million. Losses were -$62.72 million, 36.0% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for Albireo Pharma stock is "Strong Buy." The 12-month stock price forecast is 70.71, which is an increase of 92.78% from the latest price.